Controlled-release and stratified cyclodextrin inclusion complex vehicles
AssigneeCZAP Research and Development LLC
InventorAl Czap
Life of this patent
Estimating the term…
Abstract
The invention provides cyclodextrin inclusion complex delivery vehicles, in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials.
Claims21
1-12. (canceled)
A method for treating pain and/or inflammation and ameliorating toxicity caused by acetaminophen usage and/or overdose, comprising orally administering to a human subject in need thereof an effective amount of a composition comprising:
- a cyclodextrin having a cavity;
- N-acetylcysteine and acetaminophen retained as stacked guest molecules within the cavity of the cyclodextrin, forming a cyclodextrin inclusion complex;
- a pharmaceutically acceptable carrier for oral delivery of the cyclodextrin inclusion complex, wherein the N-acetylcysteine and acetaminophen are retained in the cyclodextrin inclusion complex within the pharmaceutically acceptable carrier;
- and,
- an enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin retaining the N-acetylcysteine and acetaminophen, wherein the cyclodextrin-degrading activity is activated on oral delivery of the composition to a human subject so as to release the N-acetylcysteine and acetaminophen from the cyclodextrin cavity.
A method of formulating a composition for oral delivery to a human subject in need thereof, the method comprising:
- providing a cyclodextrin having a cavity, wherein the cyclodextrin is an alpha-cyclodextrin, a beta-cyclodextrin, or a gamma-cyclodextrin;
- admixing the cyclodextrin with N-acetylcysteine and acetaminophen so that N-acetylcysteine and acetaminophen are retained as stacked guest molecules within the cavity of the cyclodextrin, forming a cyclodextrin inclusion complex;
- admixing the cyclodextrin inclusion complex with a pharmaceutically acceptable carrier for oral delivery, wherein the N-acetylcysteine and acetaminophen are retained by the cyclodextrin inclusion complex within the pharmaceutically acceptable carrier;
- and,
- admixing an enzyme with the cyclodextrin inclusion complex and the pharmaceutically acceptable carrier, the enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin retaining the cyclodextrin inclusion complex, wherein the cyclodextrin-degrading activity is activated on oral delivery of the composition to a human subject so as to release the N-acetylcysteine and acetaminophen from the cyclodextrin cavity.
Dependencies are inferred from the claim text.